|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Laurie SA and Licitra L: Systemic therapy
in the palliative management of advanced salivary gland cancers. J
Clin Oncol. 24:2673–2678. 2006.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bell RB, Dierks EJ, Homer L and Potter BE:
Management and outcome of patients with malignant salivary gland
tumors. J Oral Maxillofac Surg. 63:917–928. 2005.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lima RA, Tavares MR, Dias FL, Kligerman J,
Nascimento MF, Barbosa MM, Cernea CR, Soares JR, Santos IC and
Salviano S: Clinical prognostic factors in malignant parotid gland
tumors. Otolaryngol Head Neck Surg. 133:702–708. 2005.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Guzzo M, Locati LD, Prott FJ, Gatta G,
McGurk M and Licitra L: Major and minor salivary gland tumors. Crit
Rev Oncol Hematol. 74:134–148. 2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kaplan MJ, Johns ME and Cantrell RW:
Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg.
95:165–170. 1986.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lagha A, Chraiet N, Ayadi M, Krimi S,
Allani B, Rifi H, Raies H and Mezlini A: Systemic therapy in the
management of metastatic or advanced salivary gland cancers. Head
Neck Oncol. 4(19)2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Larson DL, Lindberg RD, Lane E and
Goepfert H: Major complications of radiotherapy in cancer of the
oral cavity and oropharynx. A 10 year retrospective study. Am J
Surg. 146:531–536. 1983.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Pendleton KP and Grandis JR:
Cisplatin-based chemotherapy options for recurrent and/or
metastatic squamous cell cancer of the head and neck. Clin Med
Insights Ther. 2013(10.4137/CMT.S10409)2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chang WS, Lin CC, Chuang SC and Chiang HC:
Superoxide anion scavenging effect of coumarins. Am J Chin Med.
24:11–17. 1996.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Masamoto Y, Ando H, Murata Y, Shimoishi Y,
Tada M and Takahata K: Mushroom tyrosinase inhibitory activity of
esculetin isolated from seeds of Euphorbia lathyris L.
Biosci Biotechnol Biochem. 67:631–634. 2003.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Egan D, O'Kennedy R, Moran E, Cox D,
Prosser E and Thornes RD: The pharmacology, metabolism, analysis,
and applications of coumarin and coumarin-related compounds. Drug
Metab Rev. 22:503–529. 1990.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kok SH, Yeh CC, Chen ML and Kuo MY:
Esculetin enhances TRAIL-induced apoptosis through DR5 upregulation
in human oral cancer SAS cells. Oral Oncol. 45:1067–1072.
2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lin WL, Wang CJ, Tsai YY, Liu CL, Hwang JM
and Tseng TH: Inhibitory effect of esculetin on oxidative damage
induced by t-butyl hydroperoxide in rat liver. Arch Toxicol.
74:467–472. 2000.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Okada Y, Miyauchi N, Suzuki K, Kobayashi
T, Tsutsui C, Mayuzumi K, Nishibe S and Okuyama T: Search for
naturally occurring substances to prevent the complications of
diabetes. II. Inhibitory effect of coumarin and flavonoid
derivatives on bovine lens aldose reductase and rabbit platelet
aggregation. Chem Pharm Bull (Tokyo). 43:1385–1387. 1995.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wang CJ, Hsieh YJ, Chu CY, Lin YL and
Tseng TH: Inhibition of cell cycle progression in human leukemia
HL-60 cells by esculetin. Cancer Lett. 183:163–168. 2002.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Noguchi M, Kitagawa H, Miyazaki I and
Mizukami Y: Influence of esculetin on incidence, proliferation, and
cell kinetics of mammary carcinomas induced by
7,12-dimethylbenz[a]anthracene in rats on high- and low-fat diets.
Jpn J Cancer Res. 84:1010–1014. 1993.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Florea AM and Büsselberg D: Cisplatin as
an anti-tumor drug: Cellular mechanisms of activity, drug
resistance and induced side effects. Cancers (Basel). 3:1351–1371.
2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Osman AM, Telity SA, Telity SA, Damanhouri
ZA, Al-Harthy SE, Al-Kreathy HM, Ramadan WS, Elshal MF, Khan LM and
Kamel F: Chemosensitizing and nephroprotective effect of
resveratrol in cisplatin-treated animals. Cancer Cell Int.
15(6)2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Tikoo K, Kumar P and Gupta J:
Rosiglitazone synergizes anticancer activity of cisplatin and
reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene
(DMBA) induced breast cancer rats. BMC Cancer.
9(107)2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cho JH, Shin JC, Cho JJ, Choi YH, Shim JH
and Chae JI: Esculetin (6,7-dihydroxycoumarin): A potential cancer
chemopreventive agent through suppression of Sp1 in oral squamous
cancer cells. Int J Oncol. 46:265–271. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Park C, Jin CY, Kim GY, Choi IW, Kwon TK,
Choi BT, Lee SJ, Lee WH and Choi YH: Induction of apoptosis by
esculetin in human leukemia U937 cells through activation of JNK
and ERK. Toxicol Appl Pharmacol. 227:219–228. 2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sakagami H: Apoptosis-inducing activity
and tumor-specificity of antitumor agents against oral squamous
cell carcinoma. Jpn Dent Sci Rev. 46:173–187. 2010.
|
|
25
|
Alsahafi E, Begg K, Amelio I, Raulf N,
Lucarelli P, Sauter T and Tavassoli M: Clinical update on head and
neck cancer: Molecular biology and ongoing challenges. Cell Death
Dis. 10(540)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wen Y and Grandis JR: Emerging drugs for
head and neck cancer. Expert Opin Emerg Drugs. 20:313–329.
2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kimura Y and Sumiyoshi M: Antitumor and
antimetastatic actions of dihydroxycoumarins (esculetin or
fraxetin) through the inhibition of M2 macrophage differentiation
in tumor-associated macrophages and/or G1 arrest in tumor cells.
Eur J Pharmacol. 746:115–125. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wang G, Lu M, Yao Y, Wang J and Li J:
Esculetin exerts antitumor effect on human gastric cancer cells
through IGF-1/PI3K/Akt signaling pathway. Eur J Pharmacol.
814:207–215. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Li J, Li S, Wang X and Wang H: Esculetin
induces apoptosis of SMMC-7721 cells through
IGF-1/PI3K/Akt-mediated mitochondrial pathways. Can J Physiol
Pharmacol. 95:787–794. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lee SY, Lim TG, Chen H, Jung SK, Lee HJ,
Lee MH, Kim DJ, Shin A, Lee KW, Bode AM, et al: Esculetin
suppresses proliferation of human colon cancer cells by directly
targeting β-catenin. Cancer Prev Res (Phila). 6:1356–1364.
2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kim WK, Byun WS, Chung HJ, Oh J, Park HJ,
Choi JS and Lee SK: Esculetin suppresses tumor growth and
metastasis by targeting Axin2/E-cadherin axis in colorectal cancer.
Biochem Pharmacol. 152:71–83. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zhu X, Gu J and Qian H: Esculetin
attenuates the growth of lung cancer by downregulating Wnt targeted
genes and suppressing NF-κB. Arch Bronconeumol (Engl Ed).
54:128–133. 2018.PubMed/NCBI View Article : Google Scholar : (In English,
Spanish).
|
|
33
|
Turkekul K, Colpan RD, Baykul T, Ozdemir
MD and Erdogan S: Esculetin inhibits the survival of human prostate
cancer cells by inducing apoptosis and arresting the cell cycle. J
Cancer Prev. 23:10–17. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhang G, Xu Y and Zhou HF: Esculetin
inhibits proliferation, invasion, and migration of laryngeal cancer
in vitro and in vivo by inhibiting janus kinas (JAK)-signal
transducer and activator of transcription-3 (STAT3) activation. Med
Sci Monit. 25:7853–7863. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wang J, Lu ML, Dai HL, Zhang SP, Wang HX
and Wei N: Esculetin, a coumarin derivative, exerts in vitro and in
vivo antiproliferative activity against hepatocellular carcinoma by
initiating a mitochondrial-dependent apoptosis pathway. Braz J Med
Biol Res. 48:245–253. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Chang HT, Chou CT, Lin YS, Shieh P, Kuo
DH, Jan CR and Liang WZ: Esculetin, a natural coumarin compound,
evokes Ca(2+) movement and activation of Ca(2+)-associated
mitochondrial apoptotic pathways that involved cell cycle arrest in
ZR-75-1 human breast cancer cells. Tumour Biol. 37:4665–4678.
2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Liang C, Ju W, Pei S, Tang Y and Xiao Y:
Pharmacological activities and synthesis of esculetin and its
derivatives: A mini-review. Molecules. 22(387)2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Chu S and Ferro TJ: Sp1: Regulation of
gene expression by phosphorylation. Gene. 348:1–11. 2005.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Safe S, Imanirad P, Sreevalsan S, Nair V
and Jutooru I: Transcription factor Sp1, also known as specificity
protein 1 as a therapeutic target. Expert Opin Ther Targets.
18:759–769. 2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Black AR, Black JD and Azizkhan-Clifford
J: Sp1 and krüppel-like factor family of transcription factors in
cell growth regulation and cancer. J Cell Physiol. 188:143–160.
2001.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Louie JS, Shukla R, Richards-Kortum R and
Anandasabapathy S: High-resolution microendoscopy in
differentiating neoplastic from non-neoplastic colorectal polyps.
Best Pract Res Clin Gastroenterol. 29:663–673. 2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Shirmanova MV, Druzhkova IN, Lukina MM,
Dudenkova VV, Ignatova NI, Snopova LB, Shcheslavskiy VI, Belousov
VV and Zagaynova EV: Chemotherapy with cisplatin: Insights into
intracellular pH and metabolic landscape of cancer cells in vitro
and in vivo. Sci Rep. 7(8911)2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Simons AL, Fath MA, Mattson DM, Smith BJ,
Walsh SA, Graham MM, Hichwa RD, Buatti JM, Dornfeld K and Spitz DR:
Enhanced response of human head and neck cancer xenograft tumors to
cisplatin combined with 2-deoxy-D-glucose correlates with increased
18F-FDG uptake as determined by PET imaging. Int J Radiat Oncol
Biol Phys. 69:1222–1230. 2007.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Chirino YI, Hernández-Pando R and
Pedraza-Chaverri J: Peroxynitrite decomposition catalyst
ameliorates renal damage and protein nitration in cisplatin-induced
nephrotoxicity in rats. BMC Pharmacol. 4(20)2004.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Stewart DJ, Benjamin RS, Luna M, Feun L,
Caprioli R, Seifert W and Loo TL: Human tissue distribution of
platinum after cis-diamminedichloroplatinum. Cancer Chemother
Pharmacol. 10:51–54. 1982.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Mora Lde O, Antunes LM, Francescato HD and
Bianchi Mde L: The effects of oral glutamine on cisplatin-induced
nephrotoxicity in rats. Pharmacol Res. 47:517–522. 2003.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Tubaro A, Del Negro P, Ragazzi E, Zampiron
S and Della Loggia R: Anti-inflammatory and peripheral analgesic
activity of esculetin in vivo. Pharmacol Res Commun. 20 (Suppl
5):S83–S85. 1988.PubMed/NCBI View Article : Google Scholar
|
|
48
|
OECD: Test No. 423: Acute Oral
toxicity-Acute Toxic Class. Method. In: OECD Guidelines for the
Testing of Chemicals, Section 4. OECD Publishing, Paris, 2002.
|
|
49
|
Lee JH, Hwang EH and Lee SR: A study on
the radiosensitivity and chemosensitivity of A-253 cell line in
vitro. J Korean Acad Oral Maxillofac Radiol. 27:91–104. 1997.
|
